S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
6 Things That Will Tell You If You Are Destined for Leadership
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
6 Things That Will Tell You If You Are Destined for Leadership
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
6 Things That Will Tell You If You Are Destined for Leadership
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
6 Things That Will Tell You If You Are Destined for Leadership
NASDAQ:MRKR

Marker Therapeutics (MRKR) Stock Price, News & Analysis

$4.31
-0.29 (-6.30%)
(As of 04/12/2024 ET)
Today's Range
$4.30
$4.65
50-Day Range
$3.63
$4.91
52-Week Range
$0.76
$9.68
Volume
20,306 shs
Average Volume
20,837 shs
Market Capitalization
$38.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Marker Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.24mentions of Marker Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.02 out of 5 stars

Medical Sector

789th out of 923 stocks

Pharmaceutical Preparations Industry

372nd out of 430 stocks

MRKR stock logo

About Marker Therapeutics Stock (NASDAQ:MRKR)

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas.

MRKR Stock Price History

MRKR Stock News Headlines

Marker Therapeutics Inc (MRKR)
SHOCKING Altcoin Moves…
Bitcoin's recent price boom has sent select altcoins into an absolute FRENZY! Which is why we've gathered 27 crypto experts to share their top picks and predictions as we rapidly approach the Bitcoin halving event this month…
Marker Therapeutics (NASDAQ:MRKR) Trading Down 2.7%
SHOCKING Altcoin Moves…
Bitcoin's recent price boom has sent select altcoins into an absolute FRENZY! Which is why we've gathered 27 crypto experts to share their top picks and predictions as we rapidly approach the Bitcoin halving event this month…
PSTX, MRKR and GPRO among pre-market losers
Sales Marker Introduces AI Sales to the World
Marker Therapeutics Inc MRKR
See More Headlines
Receive MRKR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/13/2024
Next Earnings (Estimated)
5/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MRKR
Fax
N/A
Employees
67
Year Founded
2018

Profitability

Net Income
$-8,240,000.00
Net Margins
-142.62%
Pretax Margin
-424.10%

Debt

Sales & Book Value

Annual Sales
$3.31 million
Book Value
$1.58 per share

Miscellaneous

Free Float
6,757,000
Market Cap
$38.36 million
Optionable
Not Optionable
Beta
1.50

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Ms. Elizabeth Donnelly
    Director of Administration
  • Mr. Edmund Cheung
    Vice President of Human Resources
  • Dr. Nadia Agopyan Ph.D.
    Senior Vice President of Regulatory Affairs
  • Dr. Monic Stuart M.D.
    Chief Medical Officer
  • Mr. Gerald Garrett
    Senior Vice President of Clinical Operations
  • Dr. Robert Z. Florkiewicz Sr.
    Senior Director of Molecular Biology & Virology

MRKR Stock Analysis - Frequently Asked Questions

How have MRKR shares performed in 2024?

Marker Therapeutics' stock was trading at $5.50 on January 1st, 2024. Since then, MRKR stock has decreased by 21.6% and is now trading at $4.31.
View the best growth stocks for 2024 here
.

Are investors shorting Marker Therapeutics?

Marker Therapeutics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 107,900 shares, a decrease of 27.9% from the March 15th total of 149,700 shares. Based on an average daily trading volume, of 21,000 shares, the short-interest ratio is presently 5.1 days. Currently, 1.7% of the shares of the stock are short sold.
View Marker Therapeutics' Short Interest
.

When is Marker Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our MRKR earnings forecast
.

How were Marker Therapeutics' earnings last quarter?

Marker Therapeutics, Inc. (NASDAQ:MRKR) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.01. Marker Therapeutics had a negative trailing twelve-month return on equity of 39.89% and a negative net margin of 142.62%.

What other stocks do shareholders of Marker Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Flexion Therapeutics (FLXN), Geron (GERN) and Ionis Pharmaceuticals (IONS).

How do I buy shares of Marker Therapeutics?

Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRKR) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners